Insider Selling: AxoGen, Inc. (NASDAQ:AXGN) Director Sells 5,000 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the sale, the director now owns 97,899 shares of the company’s stock, valued at $1,959,937.98. This represents a 4.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AxoGen Stock Performance

Shares of AXGN stock opened at $17.77 on Friday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $21.00. The stock has a market capitalization of $787.99 million, a PE ratio of -55.53 and a beta of 1.00. The firm has a 50 day moving average of $17.87 and a two-hundred day moving average of $15.24.

Hedge Funds Weigh In On AxoGen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AXGN. Creative Planning boosted its position in AxoGen by 152.2% in the 3rd quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock valued at $418,000 after buying an additional 17,980 shares during the period. Sentry Investment Management LLC boosted its position in AxoGen by 9.3% in the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock valued at $243,000 after buying an additional 1,483 shares during the period. Principal Financial Group Inc. purchased a new position in AxoGen in the 3rd quarter valued at approximately $207,000. Primoris Wealth Advisors LLC purchased a new position in AxoGen in the 3rd quarter valued at approximately $207,000. Finally, Los Angeles Capital Management LLC purchased a new position in AxoGen in the 3rd quarter valued at approximately $279,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on AXGN shares. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of AxoGen in a report on Wednesday. Canaccord Genuity Group increased their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $20.75.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.